Search Within

Andrew Lassman

Formats
  1. Journal Article (63)
  2. Meeting Abstract (43)
  3. Book Section (5)
Groups
  1. Tow Center for Developmental Oncology (TCDO) (51)
  2. Epidemiology and Biostatistics (29)
  3. Biostatistics Service (28)
  4. Population Sciences Research Program (26)
  5. GSK Faculty (20)
  6. Radiology, Department of (20)

More Groups

People
  1. Lauren Abrey (49)
  2. Lisa De Angelis (49)
  3. Katherine Panageas (25)
  4. Craig Nolan (19)
  5. Igor Gavrilovic (18)
  6. Adilia Hormigo (16)

More People

Years
  1. 2020 (1)
  2. 2019 (2)
  3. 2017 (1)
  4. 2015 (2)
  5. 2014 (3)
  6. 2013 (5)

More Years

Publications
  1. Neuro-Oncology (38)
  2. Journal of Clinical Oncology (21)
  3. Journal of Neuro-Oncology (14)
  4. Clinical Cancer Research (4)
  5. International Journal of Radiation Oncology, Biology, Physics (4)
  6. Neurology (3)

More Publications

Publishers
  1. Oxford University Press (38)
  2. American Society of Clinical Oncology (21)
  3. Springer (19)
  4. Elsevier Inc. (8)
  5. American Association for Cancer Research (5)
  6. Lippincott Williams & Wilkins (4)

More Publishers

Results (111)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of dasatinib in target selected patients with recurrent glioblastoma (RTOG 0627)
    Meeting Abstract

    Lassman, A. B.; Wang, M. H.; Gilbert, M. R.; Aldape, K. D.; Beumer, J. J.; Wright, J.; Takebe, N.; Puduvalli, V. K.; Hormigo, A.; Gaur, R.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Preliminary data from a multicenter, phase II, randomized, noncomparative clinical trial of radiation therapy and temozolomide with or without vandetanib in newly-diagnosed glioblastoma
    Meeting Abstract

    Lee, E. Q.; Batchelor, T. T.; Lassman, A. B.; Schiff, D. S.; Kaley, T. J.; Wong, E. T.; Mikkelsen, T.; Purow, B. W.; Drappatz, J.; Norden, A. D.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma
    Meeting Abstract

    Omuro, A.; Beal, K.; Correa, D.; Chan, T.; DeAngelis, L.; Gavrilovic, I.; Nolan, C.; Hormigo, A.; Lassman, A. B.; Kaley, T.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Time trends in treatment of anaplastic oligodendroglial tumors
    Meeting Abstract

    Panageas, K. S.; Iwamoto, F. M.; Cloughesy, T. F.; Aldape, K. D.; Rivera, A. L.; Eichler, A. F.; Louis, D. N.; Paleologos, N. A.; Fisher, B. J.; Ashby, L. S.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors
    Meeting Abstract

    Reiner, A. S.; Panageas, K. S.; Iwamoto, F. M.; Cloughesy, T. F.; Aldape, K. D.; Rivera, A. L.; Eichler, A. F.; Louis, D. N.; Paleologos, N. A.; Fisher, B. J.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • A phase i trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma
    Journal Article

    Nghiemphu, P. L.; Wen, P. Y.; Lamborn, K. R.; Drappatz, J.; Robins, H. I.; Fink, K.; Malkin, M. G.; Lieberman, F. S.; Deangelis, L. M.; Torres-Trejo, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2011)

    Fulltext@MSK | Save
  • Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Journal Article

    Iwamoto, F. M.; Hottinger, A. F.; Karimi, S.; Riedel, E.; Dantis, J.; Jahdi, M.; Panageas, K. S.; Lassman, A. B.; Abrey, L. E.; Fleisher, M.; more...
    Journal of Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Phase I study of perifosine (AKT inhibitor) and termsirolimus (mTOR inhibitor) for recurrent pediartic solid tumors
    Meeting Abstract

    Becher, O.; Gilheeney, S.; Khakoo, Y.; Haque, S.; Wexler, L.; Kolesar, J.; Sima, C.; Lassman, A.; Dunkel, I.
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Journal Article

    Iwamoto, F. M.; Hottinger, A. F.; Karimi, S.; Riedel, E.; Dantis, J.; Jahdi, M.; Panageas, K. S.; Lassman, A. B.; Abrey, L. E.; Fleisher, M.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
    Journal Article

    Hottinger, A. F.; Iwamoto, F. M.; Karimi, S.; Riedel, E.; Dantis, J.; Park, J.; Panageas, K. S.; Lassman, A. B.; Abrey, L. E.; Fleisher, M.; more...
    Annals of Neurology (2011)

    Fulltext@MSK | Save